Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127273041 | 12727304 | 1 | I | 2015 | 20160829 | 20160909 | 20160909 | EXP | CN-MLMSERVICE-20160826-0405149-1 | CN-ACCORD-043778 | ACCORD | GU FF, ZHANG Y, LIU YY, HONG XH, LIANG JY, TONG F, ET AL. LUNG ADENOCARCINOMA HARBORING CONCOMITANT SPTBN1-ALK FUSION, C-MET OVEREXPRESSION, AND HER-2 AMPLIFICATION WITH INHERENT RESISTANCE TO CRIZOTINIB, CHEMOTHERAPY, AND RADIOTHERAPY. JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2016; 9(1):ARTICLE NUMBER 66. | 69.00 | YR | M | Y | 0.00000 | 20160909 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127273041 | 12727304 | 1 | PS | CISPLATIN. | CISPLATIN | 1 | U | 206774 | |||||||||||
| 127273041 | 12727304 | 2 | SS | GEMCITABINE/GEMCITABINE HYDROCHLORIDE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | 91594 | ||||||||||||
| 127273041 | 12727304 | 3 | SS | CRIZOTINIB | CRIZOTINIB | 1 | 0 | ||||||||||||
| 127273041 | 12727304 | 4 | SS | NEDAPLATIN | NEDAPLATIN | 1 | 0 | ||||||||||||
| 127273041 | 12727304 | 5 | SS | BEVACIZUMAB | BEVACIZUMAB | 1 | U | 0 | |||||||||||
| 127273041 | 12727304 | 6 | SS | PEMETREXED | PEMETREXED | 1 | U | 0 | |||||||||||
| 127273041 | 12727304 | 7 | SS | PACLITAXEL/PACLITAXEL LIPOSOME | PACLITAXEL | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127273041 | 12727304 | 1 | Lung adenocarcinoma |
| 127273041 | 12727304 | 2 | Lung adenocarcinoma |
| 127273041 | 12727304 | 3 | Lung adenocarcinoma |
| 127273041 | 12727304 | 4 | Lung adenocarcinoma |
| 127273041 | 12727304 | 5 | Lung adenocarcinoma |
| 127273041 | 12727304 | 6 | Lung adenocarcinoma |
| 127273041 | 12727304 | 7 | Lung adenocarcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127273041 | 12727304 | LT |
| 127273041 | 12727304 | DE |
| 127273041 | 12727304 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127273041 | 12727304 | Brain cancer metastatic | |
| 127273041 | 12727304 | Drug ineffective | |
| 127273041 | 12727304 | General physical health deterioration | |
| 127273041 | 12727304 | Lung cancer metastatic | |
| 127273041 | 12727304 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127273041 | 12727304 | 1 | 201509 | 201510 | 0 | |
| 127273041 | 12727304 | 2 | 201507 | 0 | ||
| 127273041 | 12727304 | 3 | 2015 | 0 | ||
| 127273041 | 12727304 | 4 | 201507 | 0 | ||
| 127273041 | 12727304 | 5 | 201509 | 201510 | 0 | |
| 127273041 | 12727304 | 6 | 201509 | 201510 | 0 | |
| 127273041 | 12727304 | 7 | 20151027 | 0 |